Market Currents
Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price...
-
Tuesday, February 7, 2012, 9:05 AM ETWedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price target. Analysts with the firm expect that not only will Gattex win FDA approval, but that the cancer drug will also deliver $252M in global revenue in 2015.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
